Compare Gitlab Inc (GTLB) vs Indivior Pharmaceuticals Inc. Common Stock (INDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Indivior Pharmaceuticals Inc. Common Stock — how do they compare? Gitlab Inc trades at $52.23 (market cap $8.86B), while Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.03B). The key difference: Gitlab Inc is far larger — about 2.2× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Gitlab Inc is trading nearer its 52-week high, Indivior Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Indivior Pharmaceuticals Inc. Common Stock for 0 Days on average.
| GTLB | INDV | |
|---|---|---|
Market Cap | $8.86B | $4.03B |
Volume | 6,160,270 | 2,781,171 |
Sector | Technology | Health |
52-Week High | $56.01 | $41.83 |
52-Week Low | $19.42 | $24.09 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $7.60B | $4.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $51.95, down 7.25% over 24 hours but maintains strong technical momentum with bullish moving averages. The company shows impressive revenue growth, reaching $759M in 2025, with consistent earnings beats in recent quarters. High gross margins of 85.75% highlight operational efficiency, though profitability remains negative. Recent news highlights AI-driven demand and strong Q2 results with raised guidance, fueling investor optimism despite the stock trading near consensus price targets.
Outlook remains positive with accelerating AI adoption and sales momentum, though risks include persistent negative cash flow and high valuation multiples. Analyst consensus leans Hold (60%) with a $49.71 target, suggesting limited near-term upside. Key catalysts include Q3 earnings and continued execution on AI strategy, while competition and macroeconomic pressures pose challenges to sustained growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →
